MADRID, 6 Nov. (EUROPA PRESS) -
PharmaMar has received a payment of 10 million dollars (9.3 million euros) from Janssen in compliance with one of the commercial milestones of its license agreement related to Yondelis --trabectedin-- in the United States, as announced this Monday the pharmaceutical company to the National Securities Market Commission (CNMV).
In August 2019, both companies signed a new licensing agreement that replaced the one from 2001, according to which Janssen reserved the right to "exclusively" sell and distribute Yondelis in the United States.
Currently, Yondelis is approved in more than 70 countries for the treatment of soft tissue sarcoma and also in some of these countries for ovarian cancer.
PharmaMar recorded a net profit of 7.95 million euros during the first nine months of this year, which represents a decrease of 82% compared to the same period of the previous year due to the pressure on Yondelis' sales prices and the increasing effort in R&D to develop new treatments.